UniProtKB/Swiss-Prot O15245: Variant p.Gly401Ser

Solute carrier family 22 member 1
Gene: SLC22A1
Feedback?

Variant information Variant position:

401 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Serine (S) at position 401 (G401S, p.Gly401Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Affects transporter activity; reduction of MPP(+), serotonin and TEA uptake; no MPP(+) uptake when associated with L-160. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs34130495 [ dbSNP | Ensembl ]

Sequence information Variant position:

401 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

554 The length of the canonical sequence.
Location on the sequence:

YSALVEIPGAFIALITIDRV G RIYPMAMSNLLAGAACLVMI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YSALVEIPGAFIALITIDRVGRIYPMAMSNLLAGAACLVMI

Mouse                         YSSLVEFPAAFIILVTIDRIGRIYPIAASNLVAGAACLLMI

Rat                           YSSLVEFPAAFIILVTIDRIGRIYPIAASNLVTGAACLLMI

Pig                           YSALVEFPAAFVILLIIDRFGRLYLLAGSNLLAGAACFFMI

Bovine                        YSALVEFPAGFIILVTIDRFGRRYPLATSNLAAGLACFLMI

Rabbit                        YSSLVEFPAAFVILVTIDRVGRIYPMAASNLAAGVASVILI

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 554	Solute carrier family 22 member 1
Topological domain	398 – 402	Cytoplasmic
Alternative sequence	354 – 554	Missing. In isoform 4.

Literature citations
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.
Kerb R.; Brinkmann U.; Chatskaia N.; Gorbunov D.; Gorboulev V.; Mornhinweg E.; Keil A.; Eichelbaum M.; Koepsell H.;
Pharmacogenetics 12:591-595(2002)
Cited for: VARIANTS CYS-61; ARG-88; PHE-160; SER-401 AND MET-420 DEL; CHARACTERIZATION OF VARIANTS CYS-61; ARG-88; PHE-160; SER-401 AND MET-420 DEL; FUNCTION; TRANSPORTER ACTIVITY; MISCELLANEOUS; Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.
Shu Y.; Leabman M.K.; Feng B.; Mangravite L.M.; Huang C.C.; Stryke D.; Kawamoto M.; Johns S.J.; DeYoung J.; Carlson E.; Ferrin T.E.; Herskowitz I.; Giacomini K.M.;
Proc. Natl. Acad. Sci. U.S.A. 100:5902-5907(2003)
Cited for: VARIANTS PHE-14; CYS-61; PHE-85; PHE-160; LEU-189; VAL-220; LEU-341; HIS-342; SER-401; VAL-408; MET-420 DEL; ILE-440; ILE-461; ARG-465 AND MET-488; CHARACTERIZATION OF VARIANTS PHE-14; CYS-61; PHE-85; PHE-160; LEU-189; VAL-220; LEU-341; HIS-342; SER-401; VAL-408; MET-420 DEL; ILE-440; ILE-461; ARG-465 AND MET-488; MUTAGENESIS OF GLY-465; FUNCTION; SUBCELLULAR LOCATION; MISCELLANEOUS;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.